Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABX 464

Drug Profile

ABX 464

Alternative Names: ABX-464

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Splicos
  • Developer Abivax
  • Class Anti-inflammatories; Antirheumatics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Rev gene product inhibitors; RNA cap-binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 21 Nov 2019 Phase-II clinical trials in Ulcerative colitis in Slovakia, Slovenia, Belgium, Hungary (PO) (EudraCT2019-000733-39) (NCT04023396)
  • 24 Oct 2019 Phase-II clinical trials in Rheumatoid arthritis in Hungary, Poland (PO) (EudraCT2019-001578-27) (NCT04049448)
  • 08 Aug 2019 Abivax plans a follow up phase IIa trial for Rheumatoid arthritis (NCT04049448)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top